An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer.

A wide inter-individual variability in the therapeutic response to cyclin-dependent kinases 4 and 6 inhibitors (CDKis) has been reported. We herein present a case series of five patients treated with either palbociclib or ribociclib referred to our clinical pharmacological counselling, including therapeutic drug monitoring (TDM), pharmacogenetics, and drug-drug interaction analysis to support clinicians in the management of CDKis treatment for metastatic breast cancer. Patients' plasma samples for TDM analysis were collected at steady state and analyzed by an LC-MS/MS method for minimum plasma concentration (C

Informations de copyright

Copyright © 2022 Roncato, Gerratana, Palmero, Gagno, Poetto, Peruzzi, Zanchetta, Posocco, De Mattia, Canil, Alberti, Orleni, Toffoli, Puglisi and Cecchin.

Déclaration de conflit d'intérêts

LG reports consulting or advisory role: Lilly, Novartis. FP reports honoraria: Roche, MSD, AstraZeneca, Novartis, Lilly, Pfizer, Pierre Fabre, and Daiichi Sankyo; consulting or advisory role: Roche, Amgen, Lilly, Novartis, Pfizer, and Eisai; research funding: Eisai, AstraZeneca, and Roche; travel, accommodations, and expenses: Roche and Celgene. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.